Share on StockTwits

TherapeuticsMD (NASDAQ:TXMD) CEO Robert G. Finizio sold 50,000 shares of the stock on the open market in a transaction dated Friday, February 21st. The shares were sold at an average price of $6.17, for a total value of $308,500.00. Following the completion of the transaction, the chief executive officer now directly owns 22,011,586 shares of the company’s stock, valued at approximately $135,811,486. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of TherapeuticsMD (NASDAQ:TXMD) traded down 1.61% during mid-day trading on Friday, hitting $6.13. 598,574 shares of the company’s stock traded hands. TherapeuticsMD has a 52 week low of $1.65 and a 52 week high of $6.90. The stock’s 50-day moving average is $5.90 and its 200-day moving average is $4.19. The company’s market cap is $888.7 million.

A number of analysts have recently weighed in on TXMD shares. Analysts at Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research note on Tuesday, January 28th. They now have a $9.00 price target on the stock, up previously from $7.25. Finally, analysts at Cowen and Company initiated coverage on shares of TherapeuticsMD in a research note on Wednesday, January 8th. They set an “outperform” rating on the stock.

TherapeuticsMD, Inc promotes, distributes and sells certain products developed and sold by Spectrum Health Network, Inc (NASDAQ:TXMD) relative to its digital media network.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.